Ignite Creation Date:
2024-06-16 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 3:30 PM
Study NCT ID:
NCT06434480
Status:
RECRUITING
Last Update Posted:
2024-06-24
First Post:
2024-05-14
Brief Title:
SBRT in HCC With Oligoprogression on Atezo-Bev
Sponsor:
Chinese University of Hong Kong
Organization:
Chinese University of Hong Kong
Study Overview
Official Title:
Stereotactic Body Radiotherapy SBRT in Advanced Hepatocellular Carcinoma With Oligoprogression on Atezolizumab Plus Bevacizumab
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
HCC is a huge healthcare burden in Hong Kong and is one of the top 5 cancers in terms of incidence and mortality in Hong Kong Patients with advanced HCC are treated with immunotherapy-based combination atezolizumab plus bevacizumab as first-line treatment as a standard of care At the moment there is limited evidence to guide subsequent treatments after patients progressed on atezolizumab plus bevacizumab Oligoprogression is a term used to describe patients who had limited progression usually less than 3 sites on systemic therapy with the rest of the lesions controlled Previous studies in non-HCCs have shown that addition of locoregional treatment eg radiotherapy may prolong the use of systemic therapy resulting in improved survival but this has been relatively unexplored for HCC In this prospective single-arm study we aim to evaluate the treatment outcome efficacy and safety of the addition of radiotherapy to oligoprogressive sites for patients who had limited progression on atezolizumab plus bevacizumab
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None